Ferring enters into worldwide OmniAb® platform license agreement with Ligand
Ferring Pharmaceuticals announced today that it has entered into a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies for a range of indications. Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology.
“Antibody-based therapies improve the quality of life and care for patients with a wide range of conditions but have not been fully investigated, in particular in the area of reproductive medicine and women’s health,” said Armin Metzger, Senior Vice President, Head of Global Pharmaceutical Research and Development, Ferring Pharmaceuticals. “This agreement expands Ferring’s growing capabilities in biologics and broadens our historical focus on peptides, opening up significant opportunities for discoveries that will help patients to live better lives.”
Ligand's OmniAb® platforms produce highly diversified, fully human antibody repertoires optimized in vivo (in a living organism) for therapeutic efficacy and reduced immunogenicity.
Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments, and tiered royalties for each product developed by Ferring that incorporates an OmniAb antibody. Specific financial details of this transaction are not disclosed.
- Ends -
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 7,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information, visit www.ferring.com.
Ferring is on Twitter. Follow us @Ferring at http://twitter.com/Ferring
About OmniAb ®
OmniAb is a three-species transgenic-animal platform consisting of four different technologies used for producing mono- and bispecific human therapeutic antibodies. OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as effectively as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic® is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. OmniChicken™ is the industry’s first human monoclonal antibody technology based on chickens. The four technologies use patented technology, have broad freedom to operate and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono-and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.
Ferring Corporate Communications Team:
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Project Management Institute Launches New Reports on Navigating the New Normal of Disruptive Technologies During Seventh Annual PMO Symposium®12.11.2018 16:43 | Pressemelding
Project Management Institute (PMI) today unveiled three thought leadership reports focused on navigating the new normal of disruptive technologies. The new reports were released during the organization’s seventh annual PMO Symposium® in Washington D.C., where more than 650 of the world’s top project management office (PMO) executives, organizational leaders and senior decision makers have gathered to discuss how disruptive technologies—such as cloud solutions, internet of things (IoT) and artificial intelligence (AI)—have changed the way organizations do business and transformed entire industries. Throughout 2018, PMI and partners, have been exploring disruptive technologies and how organizations are using them to achieve their goals in these changing times. While no one single factor can drive benefits realization, leading organizations understand that proven project management practices lead to greater success and less waste. Produced in partnership with Accenture, PMI’s report — For
Separate Independent Studies Found that PREVENA™ Therapy Reduced Complications Following Breast Cancer Surgery and Breast Reconstruction12.11.2018 14:00 | Pressemelding
KCI, an Acelity Company, announced today that recently published data stemming from two studies demonstrate that closed incision negative pressure therapy (ciNPT) with the PREVENA™ Incision Management System reduced postsurgical wound complication potential in patients recovering from oncological breast surgery and breast reconstruction, respectively. One study titled, “The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes,” showed that patients who received ciNPT with the PREVENA™ System had significantly lower rates of overall complications and returns to the operating room compared to those in the standard of care (SOC) for incision management after breast reconstruction post-mastectomy group. In addition, patients in the PREVENA™ Therapy group overall had a shorter mean time to complete removal of all drains than the SOC group, averaging 9.9 days versus 13.1, respectively.1 In a separate study titled, “Closed Incision Negative Press
Itron Invites Innovators to Participate in Smart City Challenge12.11.2018 13:45 | Pressemelding
Itron, Inc. (NASDAQ: ITRI) is calling for hardware and software vendors to submit their products and solutions to the inaugural Itron Smart City Challenge. IoT solution providers will compete for the chance to work with leading smart cities, including Glasgow and the City of London, to deploy breakthrough solutions. Applications are due by Jan. 4, 2019. Participants are invited to develop solutions to address challenges defined by the participating cities. Glasgow: Improve travel choices and experience during events in the city while promoting the overall city center offer The City of Glasgow is one of the world’s top sporting cities and a major destination for conferences and concerts. Many thousands of people come to the city on a regular basis to experience its year-round calendar of events. However, this brings significant challenges in getting people safely and conveniently around the city to their location. It also impacts residents and particularly, the public transport system.
US-Based Lineage Logistics Acquires UK Cold Storage, Frozen Food and Logistics Service Provider Yearsley Group12.11.2018 12:00 | Pressemelding
Lineage Logistics Holdings, LLC (“Lineage” or the “Company”), the world’s most innovative and trusted provider of temperature-controlled supply chain solutions, today announced it has acquired Yearsley Group Limited (“Yearsley”), a leading temperature-controlled logistics service provider and frozen food distributor in the UK. Financial terms of the transaction were not disclosed. “Yearsley has demonstrated a strong commitment to developing longstanding, bespoke customer relationships that is consistent with how we do business at Lineage. Bringing Yearsley into the Lineage family enables us to better serve customers in the UK market and further reinforces our international logistics capabilities,” said Greg Lehmkuhl, President and Chief Executive Officer of Lineage Logistics. “Our acquisition by Lineage is a tremendous opportunity for Yearsley customers and employees alike,” said Jonathan Baker, Chief Executive of Yearsley Group. “Lineage’s commitment to innovation and service is unmat
B2BX Cryptocurrency Exchange Secures Full Regulatory Approval in Estonia12.11.2018 09:29 | Pressemelding
B2BX Exchange, a leading professional digital asset trading platform, announced today that it has received approval for a regulatory licence from the Estonian Financial Intelligence Unit (FIU). The licence means that B2BX will be able to operate as a completely regulated exchange for trading cryptocurrencies and makes it one of the first exchanges in Europe to secure this form of recognition. B2BX Exchange, part of the B2Broker group of companies, applied for its licence in Estonia due to the country’s reputation for being highly innovative and technology-friendly. Furthermore, the EU-member country continues to take a leading stance in the advancement of blockchain technologies and cryptocurrency regulation. The licence, which comes into effect shortly, will open the door for B2BX Exchange to provide an extended level of services which currently includes a crypto-to-crypto service and soon to be crypto-to-fiat, as well as providing peace of mind for B2BX Exchange users by way of incre
GSMA Elects New Board Members and Announces Orange Chairman and CEO Stéphane Richard as Chair12.11.2018 09:00 | Pressemelding
The GSMA today announced that it has elected new members of the GSMA Board for the two-year period from January 2019 through December 2020. The GSMA Board has also elected Stéphane Richard, Chairman and Chief Executive Officer of Orange Group as Chair, and Chua Sock Koong, Group Chief Executive Officer of Singtel Group as Deputy Chair. As GSMA Chair, Richard will oversee the strategic direction of the organisation, which represents more than 750 of the world’s mobile operators, as well as over 350 companies in the broader mobile ecosystem. “I am honoured to be elected to serve as Chair of the GSMA and look forward to working closely with the rest of the Board, the GSMA leadership team and our entire membership to address the critical issues facing our industry and our customers,” said Stéphane Richard, Chairman and Chief Executive Officer of Orange. “Mobile operators and our wider industry have a key role to play in promoting a safer and more inclusive digital world, while building the